217 related articles for article (PubMed ID: 28708902)
1. Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma.
Goebel J; Sulke M; Lazik-Palm A; Goebel T; Dechêne A; Bellendorf A; Mueller S; Umutlu L; Theysohn J
PLoS One; 2017; 12(7):e0181488. PubMed ID: 28708902
[TBL] [Abstract][Full Text] [Related]
2. Hepatic volume changes after lobar selective internal radiation therapy (SIRT) of hepatocellular carcinoma.
Theysohn JM; Ertle J; Müller S; Schlaak JF; Nensa F; Sipilae S; Bockisch A; Lauenstein TC
Clin Radiol; 2014 Feb; 69(2):172-8. PubMed ID: 24209871
[TBL] [Abstract][Full Text] [Related]
3. Radiation lobectomy: time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection.
Vouche M; Lewandowski RJ; Atassi R; Memon K; Gates VL; Ryu RK; Gaba RC; Mulcahy MF; Baker T; Sato K; Hickey R; Ganger D; Riaz A; Fryer J; Caicedo JC; Abecassis M; Kulik L; Salem R
J Hepatol; 2013 Nov; 59(5):1029-36. PubMed ID: 23811303
[TBL] [Abstract][Full Text] [Related]
4. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting?
Edeline J; Lenoir L; Boudjema K; Rolland Y; Boulic A; Le Du F; Pracht M; Raoul JL; Clément B; Garin E; Boucher E
Ann Surg Oncol; 2013 Aug; 20(8):2518-25. PubMed ID: 23494107
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
6. Favorable survival time provided with radioembolization in hepatocellular carcinoma patients with and without portal vein thrombosis.
Ozkan ZG; Poyanli A; Ucar A; Kuyumcu S; Akyuz F; Keskin S; Saglam S; Yilmaz E; Karaca C; Turkmen C
Cancer Biother Radiopharm; 2015 Apr; 30(3):132-8. PubMed ID: 25760644
[TBL] [Abstract][Full Text] [Related]
7. Superselective yttrium-90 radioembolization for hepatocellular carcinoma yields high response rates with minimal toxicity.
Padia SA; Kwan SW; Roudsari B; Monsky WL; Coveler A; Harris WP
J Vasc Interv Radiol; 2014 Jul; 25(7):1067-73. PubMed ID: 24837982
[TBL] [Abstract][Full Text] [Related]
8. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
9. Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization.
Garlipp B; de Baere T; Damm R; Irmscher R; van Buskirk M; Stübs P; Deschamps F; Meyer F; Seidensticker R; Mohnike K; Pech M; Amthauer H; Lippert H; Ricke J; Seidensticker M
Hepatology; 2014 May; 59(5):1864-73. PubMed ID: 24259442
[TBL] [Abstract][Full Text] [Related]
10. Survival benefit of radioembolization for inoperable hepatocellular carcinoma using yttrium-90 microspheres.
Kwok PC; Leung KC; Cheung MT; Lam TW; Szeto LT; Chou SQ; Chia NH; Tong CM; Yuen PK; Cheung CH; Law CK
J Gastroenterol Hepatol; 2014 Nov; 29(11):1897-904. PubMed ID: 24734957
[TBL] [Abstract][Full Text] [Related]
11. Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study.
Ahmadzadehfar H; Meyer C; Ezziddin S; Sabet A; Hoff-Meyer A; Muckle M; Logvinski T; Schild HH; Biersack HJ; Wilhelm K
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):80-90. PubMed ID: 23064545
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Study on Hepatobiliary Scintigraphy to Monitor Regional Liver Function in
van der Velden S; Braat MNGJA; Labeur TA; Scholten MV; van Delden OM; Bennink RJ; de Jong HWAM; Lam MGEH
J Nucl Med; 2019 Oct; 60(10):1430-1436. PubMed ID: 30954942
[TBL] [Abstract][Full Text] [Related]
14. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
[TBL] [Abstract][Full Text] [Related]
16. Response to radioembolization with yttrium-90 resin microspheres may allow surgical treatment with curative intent and prolonged survival in previously unresectable hepatocellular carcinoma.
Iñarrairaegui M; Pardo F; Bilbao JI; Rotellar F; Benito A; D'Avola D; Herrero JI; Rodriguez M; Martí P; Zozaya G; Dominguez I; Quiroga J; Sangro B
Eur J Surg Oncol; 2012 Jul; 38(7):594-601. PubMed ID: 22440743
[TBL] [Abstract][Full Text] [Related]
17. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma.
Zhan C; Ruohoniemi D; Shanbhogue KP; Wei J; Welling TH; Gu P; Park JS; Dagher NN; Taslakian B; Hickey RM
J Vasc Interv Radiol; 2020 Jan; 31(1):25-34. PubMed ID: 31422022
[TBL] [Abstract][Full Text] [Related]
18. Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma.
Palard X; Edeline J; Rolland Y; Le Sourd S; Pracht M; Laffont S; Lenoir L; Boudjema K; Ugen T; Brun V; Mesbah H; Haumont LA; Loyer P; Garin E
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):392-401. PubMed ID: 29177870
[TBL] [Abstract][Full Text] [Related]
19. Treatment planning and volumetric response assessment for Yttrium-90 radioembolization: semiautomated determination of liver volume and volume of tumor necrosis in patients with hepatic malignancy.
Monsky WL; Garza AS; Kim I; Loh S; Lin TC; Li CS; Fisher J; Sandhu P; Sidhar V; Chaudhari AJ; Lin F; Deutsch LS; Badawi RD
Cardiovasc Intervent Radiol; 2011 Apr; 34(2):306-18. PubMed ID: 20683722
[TBL] [Abstract][Full Text] [Related]
20. Portal vein embolization with N-butyl cyanoacrylate before partial hepatectomy in patients with hepatocellular carcinoma and underlying cirrhosis or advanced fibrosis.
Denys A; Lacombe C; Schneider F; Madoff DC; Doenz F; Qanadli SD; Halkic N; Sauvanet A; Vilgrain V; Schnyder P
J Vasc Interv Radiol; 2005 Dec; 16(12):1667-74. PubMed ID: 16371534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
